We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy is for the treat... Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy is for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from North America. Show more
First disclosure from Cohort D of the Phase 2 CARTITUDE-2 study investigating CARVYKTI® in patients who had suboptimal response to frontline ASCT in an oral presentation at ASCO & EHA An...
U.S. index futures show an upward trend in Monday’s pre-market following the best week of the year for the Dow Jones. With Wall Street on alert, the market eagerly awaits the release of new...
CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $157 million EC and US FDA approved CARVYKTI® label expansion in earlier lines of treatment for adult patients...
New indication for this one-time infusion may provide patients with a treatment-free respite as early as first relapse Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader...
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Monday, May 13, 2024, to review...
New indication for this one-time infusion may provide patients with a treatment-free respite as early as first relapse Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
